birtamimab
AssetAlso ELT1-01, Hu2A4, NEOD001
Monoclonal antibody targeting cryptic epitope on misfolded light chain aggregates to promote clearance
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Proteostasis
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Light chain (al) amyloidosis
Phase 3, Terminated, NCT04973137, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.